ArticleFrontiers in human neuroscience2025
Predicting progression from SeLECTS with SWAS to EE-SWAS: risk factor identification and model development.
Article in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study sought to identify early risk factors and develop a predictive model for progression from self-limited epilepsy with centrotemporal spikes (SeLECTS) accompanied by spike-and-wave activation in sleep (SWAS) to epileptic encephalopathy with SWAS (EE-SWAS), aiming to facilitate early clinical intervention. Methods: From a pediatric cohort with spike-and-wave index >50%, we analyzed 77 SeLECTS patients (33 progressed to EE-SWAS, 36 remained stable over ≥2 years of follow-up). Baseline clinical and EEG features were comprehensively evaluated. Multivariate logistic regression identified independent predictors of cognitive regression, which were incorporated into a nomogram-based predictive model. Model performance was assessed using the C-index in both derivation and external validation cohorts. Results: Prolonged spike-and-wave clusters, high-amplitude spikes with secondary generalization, and younger age at first seizure emerged as independent predictors of EE-SWAS progression. The nomogram model demonstrated high discriminative ability, with a C-index of 0.932 in the derivation cohort and 0.934 in external validation. Conclusion: This study provides the first validated tool for early risk stratification in SWAS-associated SeLECTS, enabling clinicians to anticipate EE-SWAS progression and optimize therapeutic strategies. The model's robustness supports its potential utility in clinical decision-making to mitigate cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.